Related Experiment Video

Updated: Aug 3, 2026

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models
10:27

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models

Published on: October 20, 2017

Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats

X Qiang1, J Satoh, M Sagara

  • 1Third Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

Diabetologia
|December 2, 1998
PubMed

Insights

Troglitazone, a free-radical scavenger, improved diabetic peripheral neuropathy in rats by reducing oxidative stress and inflammation. This therapeutic effect occurred independently of blood glucose control, highlighting its potential for managing diabetic complications.

Area of Science:

  • Biomedical Science
  • Pharmacology
  • Neuroscience

Background:

  • Diabetic peripheral neuropathy is a debilitating complication associated with oxidative stress and inflammation.
  • Free-radical scavengers and TNF-alpha inhibitors show promise in mitigating diabetic neuropathy.
  • Troglitazone, a thiazolidinedione, possesses both free-radical scavenging and TNF-alpha inhibitory properties.

Purpose of the Study:

  • To investigate the efficacy of troglitazone in preventing and treating streptozotocin (STZ)-induced diabetic peripheral neuropathy in rats.
  • To determine if troglitazone's effects are linked to its antioxidant and anti-inflammatory actions.
  • To assess troglitazone's impact on nerve function and morphology independent of glycemic control.

Main Methods:

  • Rats with STZ-induced diabetes were treated with varying doses of troglitazone for 24 weeks.
  • Measurements included blood glucose, body weight, serum lipoperoxides, and serum TNF-alpha activity.
  • Nerve conduction velocity (MNCV) and morphometric analyses of tibial nerves were performed.

Main Results:

  • Troglitazone treatment did not alter blood glucose levels or body weight in diabetic rats.
  • Troglitazone significantly reduced serum lipoperoxide concentrations and TNF-alpha activity.
  • Troglitazone administration improved MNCV and preserved myelinated nerve fiber morphology in diabetic rats.

Conclusions:

  • Troglitazone demonstrates a protective effect against diabetic peripheral neuropathy in STZ-induced diabetic rats.
  • The beneficial effects of troglitazone are attributed to its antioxidant and anti-inflammatory properties, not glycemic control.
  • Troglitazone represents a potential therapeutic agent for managing diabetic neuropathy.

More Related Videos

Preparation of Naringenin Solution for In Vivo Application08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...